Penn State researchers 3D print cell spheroids to regenerate bone tissue

At Penn State, a team of engineers and chemists has figured out how to print living cells in three dimensions—stacking them layer by layer into tiny spheres that can rebuild bone. The work addresses one of medicine's stubborn problems: when someone loses bone to severe trauma, infection, or cancer, the body often cannot heal the damage on its own. These bioprinted spheroids offer a path forward.

The researchers started with blank slate stem cells, the kind you can buy commercially. They introduced genetic switches—two specific strands of microRNA—into these undifferentiated cells. One switch, miR-148b, nudges cells toward bone growth. The other, miR-210, pushes them toward forming blood vessels. After a few days of culturing, the team assembled these genetically primed cells into spheroids, then used a precision printing technique to position them inside a gel scaffold at exact distances from one another. The result was a three-dimensional structure designed to do two things at once: regenerate bone and build the vascular network that bone tissue needs to survive.

The challenge that made this work necessary is straightforward but profound. Bone is not a single cell type. It is a complex architecture of different cells working in concert. Conventional tissue regeneration has struggled with vascularization—the formation of new blood vessels—when trying to grow bone from spheroids. Without those vessels, thick bone tissue cannot get the oxygen and nutrients it needs. Ibrahim Ozbolat, a professor of engineering science and mechanics at Penn State, explained that building tissues requires extremely precise, coordinated cellular networks. His team's aspiration-assisted bioprinting technique picks up individual spheroids and places them at specific locations within the scaffold, allowing researchers to control exactly where each cluster sits and what genetic instructions it carries.

The team tested their approach in mice with bone tissue damage. Untreated mice showed bone regeneration covering about 35 percent of the damaged area after six weeks. Mice given a control spheroid with just the scaffold achieved 93 percent coverage. But the real finding came when researchers combined both microRNA strands in alternating patterns within the scaffold. These combination groups showed even more effective bone development and vascularization. The researchers measured CD31, a protein that marks the inner lining of blood vessels, and found higher expression in the combination group—suggesting that spheroids with different cellular characteristics cooperate with one another to spur growth.

Daniel Hayes, head of the Department of Biomedical Engineering at Penn State, was clear about the intended use. This is not a treatment for a routine bone fracture. It is for someone who has suffered catastrophic trauma or lost bone to disease. The spheroids are progenitor cells—cells that will eventually help form vascularized bone while also triggering the body's own natural healing process. The work, published in Chemical Engineering Journal, was supported by the National Science Foundation and the National Institutes of Health.

What makes this moment significant is not just the science but the timing. The materials are commercially available. The techniques are scalable. As these methods move closer to clinical use, researchers say there is a huge opportunity now to establish the fundamental knowledge clinicians will need. The team plans to continue investigating the relationship between vascularization and bone growth in larger animal models, working toward the day when a surgeon might print custom bone scaffolds tailored to a patient's specific injury.